This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Squibb approved to analyze Zydus' product in ongoing India patent dispute

By Freny Patel ( February 16, 2026, 00:27 GMT | Insight) -- US pharmaceutical giant Squibb has been authorized by India’s top court to conduct technical "product-to-claim mapping" of Zydus’ anti-cancer biosimilar. The Supreme Court of India's directive of physical comparison will determine if patent infringement has occurred.Product mapping will be the decisive factor in a patent infringement battle between the US-based unit of Bristol Myers Squibb and Zydus Lifesciences, following a directive from India's top court....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login